

Cover Story
By Matthew Bin Han Ong
In an era of intensifying judicial repudiation of evidence-based guidelines and deepening public mistrust toward science, America’s screening rate for cervical cancer has been declining.
In Brief


Clinical Roundup


Drugs & Targets
Trending Stories
- OMB proposed rule could end 50% of currently active clinical trials, Stand up for Science analysis finds
- What NHS-Galleri taught us—and what it didn’t
- The NHS-Galleri trial has and will continue to provide critical insights to refine future MCED studies
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- The Directors: Directors of two Midwestern cancer centers tell us about the challenging healthcare economics in rural areas
“Institutions are feeling crunched in so many different directions” - Ian Krop named section chief of Medical Oncology and Hematology and deputy director for Clinical Affairs at Yale
















